• Indometacin Sodium: From COX to Remyelination

  2026-09-14

  Indometacin Sodium is more than a conventional COX inhibitor: it can help connect prostaglandin biology with Wnt/β-catenin-dependent oligodendrocyte repair. This guide explains how to design mechanistically discriminating assays around C6491 while separating established evidence from translational hypotheses.

• Dual HER2/VEGFR2 Targeting in TNBC Metastasis

  2026-09-13

  A 2026 study examined whether combining Lapatinib and Telatinib could suppress metastatic and angiogenic phenotypes in HER2-negative MDA-MB-231 triple-negative breast cancer cells. The work links reduced proliferation, invadopodia formation, and two-dimensional tube formation to a phenotype-first strategy for targeted cancer therapy research, while leaving direct target engagement and combination synergy unresolved.

• Organoid-Guided Therapy in Rare Neuroendocrine Cancer

  2026-09-12

  This 2026 reference study used longitudinal personalized tumor organoids and autologous tumor-infiltrating lymphocytes to map treatment response across the clinical course of a patient with chemoresistant neuroendocrine cervical cancer. Its main contribution is an integrated strategy that links organoid-guided drug discovery with immune co-culture and TIL optimization, suggesting a practical framework for individualized treatment selection in rare cancers.

• Prestained Protein Marker: F4005 Workflow Guide

  2026-09-11

  Learn how the Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa), SKU F4005, can strengthen Western blot quality control alongside cell viability, proliferation, and cytotoxicity studies. This scenario-based guide covers compatibility, protocol handling, interpretation, and practical vendor selection.

• Epalrestat Activates KEAP1/Nrf2 in Parkinson’s Models

  2026-09-11

  Jia et al. report that Epalrestat protects dopaminergic neurons in cellular and mouse Parkinson’s disease models by reducing oxidative stress and mitochondrial dysfunction. The study’s main innovation is the identification of direct KEAP1 binding and consequent Nrf2 pathway activation, extending investigation of this established aldose reductase inhibitor beyond diabetic neuropathy research.

• Dovitinib (TKI-258) Workflow for RTK Cancer Assays

  2026-09-10

  Build more informative Dovitinib assays by combining RTK phosphorylation, viability, and apoptosis readouts rather than relying on a single endpoint. A radiopathomics study offers a complementary framework for linking baseline phenotype to treatment response while clearly defining what remains experimentally untested.

• X-Gal Workflow for Cloning and β-Galactosidase Assays

  2026-09-10

  Build more reliable blue-white colony screening with a practical X-Gal workflow covering stock preparation, plate formulation, controls, and colony interpretation. The same chromogenic readout can also support lacZ reporter development, while the iRhom2 olfaction study shows where this assay is useful as an orthogonal tool rather than a substitute for molecular signaling measurements.

• EPZ5676: DOT1L Inhibition Beyond Leukemia

  2026-09-09

  EPZ5676 is a highly selective DOT1L inhibitor for dissecting H3K79 methylation in leukemia and renal fibrosis models. This article focuses on assay interpretation, cross-domain evidence, and experimental decisions that distinguish target engagement from nonspecific cytotoxicity.

• VE-822: ATR Inhibitor for DDR Research

  2026-09-09

  VE-822 is a potent and selective ATR inhibitor with a reported biochemical IC50 of 0.019 μM. Its research value centers on DNA damage response inhibition and the study of pancreatic cancer sensitization to radiation and gemcitabine.

• 5-hme-dCTP: From Reagent to Assay Design

  2026-09-08

  5-hme-dCTP is more than a modified nucleotide triphosphate: it can help build controlled substrates, interrogate polymerase behavior, and strengthen 5hmC assay interpretation. This guide connects reagent selection with rice drought-response epigenetics while defining practical limits and controls.

• Tetrahydromagnolol in CB2 Signaling Workflows

  2026-09-08

  Tetrahydromagnolol supports selective peripheral CB2 receptor activation studies while offering a built-in GPR55 antagonist counterpoint. This article shows how to connect receptor pharmacology with inflammation, analgesic mechanism, and exploratory cytoskeletal assays without overstating what is known about cross-pathway signaling.

• Dual SMAD and Wnt Inhibition for iPSC-RGC Differentiation

  2026-09-07

  Chavali and colleagues developed a chemically defined, non-genetic method that combines dual SMAD and canonical Wnt inhibition to direct human induced pluripotent stem cells toward retinal ganglion cells. The protocol improved yield and reproducibility, producing cultures with more than 80% RGC purity and enabling additional Thy-1-positive enrichment to nearly 95%, supporting robust in vitro models of glaucoma and optic neurodegeneration.

• Trichostatin A (TSA) for Epigenetic Workflows

  2026-09-07

  Trichostatin A (TSA) provides a reversible way to connect HDAC activity with histone acetylation, cell-cycle control, differentiation, and cancer phenotypes. This practical guide covers concentration planning, assay controls, senescence-informed interpretation, and troubleshooting for reproducible cell and translational workflows.

• TCAIM Reprograms Mitochondrial OGDH Proteostasis

  2026-09-05

  A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The work establishes mitochondrial proteostasis as a post-translational mechanism for tuning α-ketoglutarate dehydrogenase activity and carbohydrate metabolism.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-09-04

  Borchert et al. integrated drug-response experiments with homologous recombination repair gene-expression profiling to examine whether BRCAness identifies malignant pleural mesothelioma models susceptible to olaparib. Their findings support biomarker-guided PARP inhibition, particularly in BAP1-mutated cells, while emphasizing that the proposed treatment combinations require clinical validation.

7975 records 1/532 page Next 12345 下5页 Last page